Stockscreener 앱 받기
3.76
3.87%
0.14
Perspective Therapeutics Inc 주식(CATX)의 최신 뉴스
Perspective Therapeutics, Inc. (NYSE:CATX) Receives Average Rating of “Buy” from Analysts - Defense World
Perspective Therapeutics, Inc. (NYSE:CATX) Shares Sold by Bank of America Corp DE - Defense World
Analyzing Ratios: Perspective Therapeutics Inc (CATX)’s Financial Story Unveiled - DWinneX
The Goldilocks Isotope: Perspective Therapeutics’ ‘Just Right’ Alpha Radiotherapeutic - insights.citeline.com
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Increases Stock Position in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
Cantor Fitzgerald Forecasts CATX FY2026 Earnings - Defense World
Ameriprise Financial Inc. Sells 645,170 Shares of Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
151,610 Shares in Perspective Therapeutics, Inc. (NYSE:CATX) Acquired by Two Sigma Advisers LP - Defense World
ProShare Advisors LLC Acquires 5,011 Shares of Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
Perspective Therapeutics (NYSE:CATX) Rating Increased to Moderate Buy at Royal Bank of Canada - Defense World
Perspective Therapeutics (CATX) Price Target Raised by RBC Capital | CATX Stock News - GuruFocus
Perspective Therapeutics (CATX) Gets a Buy from Scotiabank - The Globe and Mail
RBC Capital Boosts Price Target for Perspective Therapeutics (CA - GuruFocus
Perspective Therapeutics Updates on Radiopharmaceutical Advancements - TipRanks
RBC Capital raises Perspective Therapeutics stock price target to $16 By Investing.com - Investing.com Nigeria
RBC Raises Price Target on Perspective Therapeutics to $16 From $15, Keeps Outperform, Speculative Risk - marketscreener.com
RBC Capital raises Perspective Therapeutics stock price target to $16 - Investing.com
Perspective Therapeutics, Inc. (NYSE:CATX) Shares Sold by Nuveen Asset Management LLC - Defense World
Perspective Therapeutics, Inc. (NYSE:CATX) Shares Acquired by Deutsche Bank AG - Defense World
Two Sigma Investments LP Takes $2.08 Million Position in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
Perspective Therapeutics, Inc. (CATX) Reports Positive Results for NET Treatment Trial - Insider Monkey
Perspective Therapeutics Highlights Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-?-NET at the 2025 ASCO Annual Meeting | CATX Stock News - GuruFocus
Perspective Therapeutics Provides Updated Interim Results and Safety Findings for [212Pb]VMT-α-NET at ASCO 2025 - Nasdaq
Perspective Therapeutics Highlights Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the 2025 ASCO Annual Meeting - The Manila Times
Millennium Management LLC Buys New Stake in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
Neuroendocrine Tumors Market: Epidemiology, Therapies, - openPR.com
Perspective Therapeutics Announces Voting Results By Investing.com - Investing.com Canada
Perspective Therapeutics Holds Annual Stockholders Meeting - TipRanks
Perspective Therapeutics Announces Voting Results - Investing.com
Northern Trust Corp Acquires 13,115 Shares of Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
Janus Henderson Group PLC Has $57,000 Stake in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
Perspective Therapeutics, Inc. (NYSE:CATX) Given Consensus Rating of “Buy” by Brokerages - Defense World
HC Wainwright Has Pessimistic Outlook of CATX Q3 Earnings - Defense World
Equities Analysts Offer Predictions for CATX Q1 Earnings - Defense World
Perspective Therapeutics, Inc. (CATX): Analysts See 460% Upside Potential - MSN
Head-To-Head Review: Avinger (NASDAQ:AVGR) and Perspective Therapeutics (NYSE:CATX) - Defense World
Perspective Therapeutics’ SWOT analysis: rare disease stock faces clinical hurdles - Investing.com Nigeria
Mercer Global Advisors Inc. ADV Invests $51,000 in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
Perspective Therapeutics Reports Q1 2025 Earnings - TipRanks
Perspective Therapeutics (CATX) Rating Maintained, Price Target Lowered | CATX Stock News - GuruFocus
Truist Securities Adjusts Perspective Therapeutics Price Target to $8 From $10, Maintains Buy Rating - marketscreener.com
Oppenheimer cuts CATX stock price target to $15, maintains Outperform By Investing.com - Investing.com South Africa
Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2025 Results | CATX Stock News - GuruFocus
Oppenheimer Trims Perspective Therapeutics Price Target to $15 From $16, Maintains Outperform Rating - marketscreener.com
Perspective Therapeutics, Inc. (NYSE:CATX) Shares Acquired by Wells Fargo & Company MN - Defense World
Oppenheimer cuts CATX stock price target to $15, maintains Outperform - Investing.com
Perspective Therapeutics: Q1 Earnings Snapshot - The Washington Post
Perspective Therapeutics Inc (CATX) Q1 2025 Earnings: EPS Loss of $0.25 Beats Estimate, Revenue of $0.3M Exceeds Expectations - GuruFocus
Perspective Therapeutics Reports Q1 2025 Results and Updates - TipRanks
Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2025 Results - The Manila Times
Perspective Therapeutics, Inc. Announces Clinical Updates and Recruitment Progress for Novel Radiopharmaceuticals Ahead of 2025 ASCO Meeting - Nasdaq
1.05%
0.64%
자본화:
|
볼륨(24시간):